Filters
Clonality
Type
Reactivity
Gene Name
Isotype
Host
Application
Clone
3 results for "Broad Spectrum Kinase Inhibitor" - showing 1-3
Testing Data
(PLX4720, a 7-azaindole derivative that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochemical and cellular assays. PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases (IC50:B-Raf=160 nM, BRK=130 nM, other kinases >1000nM), and potent cytotoxic effects are also exclusive to cells bearing the V600E allele (GI5010 uM). [1]Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E -bearing tumor cell lines but not in cells lacking oncogenic B-Raf. [1]In B-RafV600E -dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity. [1])
PLX-4720, Inhibitor (Cat# AAA8506422)
Full Name
PLX-4720
Purity
>99%
Pricing
$295/5 mg | $1,255/5x5 mg
Structure
Lucitanib, Inhibitor (Cat# AAA5754812)
Full Name
Lucitanib
Purity
98.00%
Pricing
$240/2 mg | $300/5 mg | $390/10 mg | $525/25 mg | $875/50 mg | $1,245/100 mg | $1,810/200 mg | $310/1 mL (in DMSO) | $7,870/5x200 mg
Chemical Structure
CTX 0294885, Inhibitor (Cat# AAA3840205)
Full Name
CTX 0294885
Purity
>98%
Pricing
$170/5 mg | $230/10 mg | $395/25 mg | $1,730/5x25 mg
